Pharmaceuticals Sector - Solvay

Key fi gures [EUR million]
Pharmaceuticals Sector
2003 2004 2005
Sales 1 832 1 745 2 270
REBIT 243 236 302
Depreciation 59 65 87
Capital expenditures 153 150 1 346
R&D 284 294 351
Headcount [1] 7 530 7 988 10 004
Sales
breakdown 2005:
EUR 2 270 million
[1] Full-time equivalents at January 1 of the following year.
R&D
expenditure 2005:
EUR 351 million
By Therapeutic fi eld
Cardiometabolics
19 %
Neuroscience
16 %
Flu vaccines
6 %
Pancreatic enzymes
7 %
Gastroenterology
18 %
By geographic area
Hormone Therapy for
Men and Women
23 %
Others
11 %
g Europe
37 % European Union (25)
8 % Other European countries
g Asia-Pacifi c
g The Americas
43 % Nafta
2 % Mercosur
g Rest of the world
By therapeutic fi eld
Cardiometabolics
27 %
Neuroscience
33 %
Flu vaccines
4 %
Pancreatic enzymes
7 %
Gastroenterology
5 %
Hormone Therapy for
Men and Women
24 %
23 %
45 %
5 %
11 %
18 %
19 %
6 %
7 %
24 % 27 2 %
7 %
4%
3 %
7 %
33 %
16 %
45 %
Werner Cautreels
Solvay Pharmaceuticals
faces fundamental
changes
Various signifi cant and
simultaneous changes in the
pharmaceuticals environment
have led to adaptations within
our own business.
Among these changes we would
mention:
– unmet medical needs;
– risk/benefi t ratios and safety
and compliance requirements
that are becoming important
criteria in gaining approvals;
– signifi cantly rising costs of
development. Post-registration
clinical work and the need to
police safe and effective product
use all add to the overall
development costs.
These are requiring companies to
redefi ne their methods of working
and their development plans to
get their molecules registered.
15
Solvay Global Annual Report 2005
Pharmaceuticals